---
title: "Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/259347819.md"
description: "Konruns announced that it has received approval from the National Medical Products Administration to conduct clinical trials for KC1036 in combination with PD-1 antibodies and platinum-based chemotherapy as first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma. KC1036 is a Class 1 innovative drug independently developed by the company, which has anti-tumor activity and good safety. Clinical research has been conducted in multiple indications, with over 300 participants involved"
datetime: "2025-09-29T12:51:02.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/259347819.md)
  - [en](https://longbridge.com/en/news/259347819.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/259347819.md)
---

# Konruns: KC1036 combined with PD-1 antibody and platinum-based chemotherapy has been approved for clinical trials as a first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma

According to the Zhitong Finance APP, Konruns (603590.SH) announced that it has recently received a clinical trial notification from the National Medical Products Administration for its Class 1 innovative chemical drug KC1036 tablets regarding "KC1036 combined with PD-1 antibody and platinum-based chemotherapy as first-line treatment for advanced recurrent or metastatic esophageal squamous cell carcinoma," and will soon commence clinical trials.

KC1036 is a Class 1 innovative chemical drug independently developed by the company, which holds global intellectual property rights for the product. KC1036 achieves anti-tumor activity by inhibiting multiple targets such as VEGFR2 and AXL. KC1036 has strong VEGFR vascular targeting, inhibiting tumor cell growth; by inhibiting AXL, it can improve the host's anti-tumor immune response, thereby avoiding tumor immune evasion. Currently, KC1036 is undergoing clinical research for multiple indications, including gastrointestinal tumors, thymic tumors, and pediatric rhabdomyosarcoma. To date, over 300 subjects have been enrolled in the KC1036 clinical study, and existing clinical research results have demonstrated outstanding anti-tumor activity, as well as good safety and tolerability

### Related Stocks

- [603590.CN](https://longbridge.com/en/quote/603590.CN.md)

## Related News & Research

- [Should You Be Adding Daewoong Pharmaceutical (KRX:069620) To Your Watchlist Today?](https://longbridge.com/en/news/286824214.md)
- [Annovis Announces Launch of Proposed Public Offering of Common Stock and Accompanying Warrants | ANVS Stock News](https://longbridge.com/en/news/286960443.md)
- [NYC Health and Hospitals says hackers stole medical data and fingerprints during breach affecting at least 1.8 million people](https://longbridge.com/en/news/286799449.md)
- [China's Bio-Thera Gets US Nod for Golimumab Biosimilar](https://longbridge.com/en/news/286880573.md)
- [While Everyone Chases AI, Pharma Keeps Getting Cheaper](https://longbridge.com/en/news/286650835.md)